Analysts Set Medpace Holdings, Inc. (NASDAQ:MEDP) PT at $357.50

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given an average recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, MarketBeat reports. Ten research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $349.30.

Several equities research analysts have commented on the stock. Mizuho decreased their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a research note on Wednesday, April 9th. TD Cowen lowered Medpace from a “buy” rating to a “hold” rating and dropped their price target for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partnrs upgraded Medpace to a “hold” rating in a research note on Monday, March 24th. Robert W. Baird lowered their target price on Medpace from $340.00 to $313.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Truist Financial reduced their price target on shares of Medpace from $333.00 to $300.00 and set a “hold” rating for the company in a research report on Wednesday.

Medpace Price Performance

NASDAQ:MEDP opened at $302.88 on Tuesday. Medpace has a one year low of $250.05 and a one year high of $459.77. The company has a market cap of $9.16 billion, a PE ratio of 23.98, a PEG ratio of 3.81 and a beta of 1.46. The firm has a 50-day moving average of $314.64 and a 200-day moving average of $332.04.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the prior year, the business posted $3.20 earnings per share. On average, equities research analysts expect that Medpace will post 12.29 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently bought and sold shares of the company. Assetmark Inc. raised its stake in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after buying an additional 29 shares during the last quarter. Proficio Capital Partners LLC increased its stake in Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after purchasing an additional 29 shares in the last quarter. Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after buying an additional 29 shares in the last quarter. HBK Sorce Advisory LLC grew its holdings in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after buying an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. increased its position in shares of Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock valued at $874,000 after acquiring an additional 30 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.